A Retrospective Analysis of the Efficacy of Ceftriaxone-Sulbactam-EDTA Combination for Suspected Biofilm Infections
Journal Title: National Journal of Laboratory Medicine - Year 2019, Vol 8, Issue 1
Abstract
ABSTRACT Introduction: Bacterial biofilms are highly recalcitrant to antibiotic treatment and thus carry important clinical repercussions. In view of rising biofilm-forming pathogens, new antibacterial approaches aimed at disrupting biofilms are needed. Aim: To determine the clinical utility of CSE-1034 (Ceftriaxone-Sulbactam-EDTA) therapy in suspected biofilm infections. Materials and Methods: Subjects with Urinary Tract Infections (UTIs) or Intra-Abdominal Infections (IAIs) with in-vivo devices (catheters, stents, etc.,) and suspected of biofilm-related infections and who received CSE-1034 as 2nd line therapy were included in this study. Based on susceptibility report, CSE-1034 therapy was started in these patients and continued or discontinued based on improvement in clinical symptoms. Results: Thirty culture-positive adult patients were included in this study. All the patients had received Pipericillin-Tazobactam (Pip-Taz) or Cefaperazone-Sulbactam empirically but none of them responded clinically. Culture susceptibility results available on day 3 have shown that isolates from 40% patients started with Pip-Taz were reported susceptible to Pip-Taz and 45% of patients started with Cefaperazone-Sulbactam were reported susceptible to antibiotic used. 100% of the isolates were susceptible to CSE-1034, 90% to Meropenem and susceptibility to Colistin was 80%. Based on culture susceptibility report and further treatment modifications done, all the patients were switched over to CSE-1034 as 2nd line treatment. A total of 27 patients responded to CSE-1034 and were cured. However, 3 patients who did not respond to CSE-1034 for 48 hour were switched over to Meropenem and reported to be cured. Conclusion: From this study, it can be suggested that CSE-1034 should be a choice of treatment over beta-lactam/beta-lactam inhibitor combinations for patients suspected of biofilm infections.
Authors and Affiliations
Sunita Gupta, Taranpreet Kaur
Keywords
Related Articles
- EP ID EP609990
- DOI 10.7860/NJLM/2019/36849:2338
- Views 98
- Downloads 0
Isolated Langerhans Cell Histiocytosis of Thyroid-Masquerading as a Thyroid Neoplasm - A Rare Case Report
ABSTRACT Langerhans Cell Histiocytosis (LCH) is a rare neoplastic disease of unknown etiology characterized by oligoclonal proliferation of langerhans cells with a varying incidence rate of 4-5.4 per 1 million individual...
Prevalence of Group A Streptococcal Carriage Rate in Asymptomatic Children
ABSTRACT Introduction: Streptococcus pyogenes is a Gram positive cocci causing respiratory infections commonly in children. Throat carriers are children in whom the organism is isolated from throat swab specimens in the...
Uterine Adenomyosis in Mullerian Remnant with Transverse Vaginal Septum with Haematocolpos in Mayer-Rokitansky-Kuster-Hauser Syndrome: A Case Report
The Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is a rare disorder characterised by failure of the uterus and vagina to develop properly in women who have normal ovarian function and normal external genitalia and seco...
Uncommon Papillary Lesions in Human Breast-Rare Pathology
Breast cancer is a lesion that usually affects female but the male community is not spared from being affected. The cause of male breast cancer is not clear but predisposing factors found are increased age over 50’s, fam...
Platelet Indicies in Pre-eclampsia and Eclampsia
Introduction: Activation of platelets due to defective placental trophoblastic invasion in the pathophysiology of pre-eclampsia and eclampsia is known. The changes in the platelet parameters and its relevance are discuss...